Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Transcode Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2023 |
4
| Dudley Robert Michael (CEO) has filed a Form 4 on Transcode Therapeutics, Inc.|
Txns:
| Bought 98,000 shares
@ $0.51, valued at
$50k
|
|
| 09/28/2023 |
8-K
| Quarterly results |
| 09/27/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 08/24/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/04/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 07/28/2023 |
8-K
| Quarterly results |
| 06/16/2023 |
SC 13D/A
| Dudley Robert Michael reports a 6% stake in TransCode Therapeutics, Inc. |
| 06/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...|
Docs:
|
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of June 6, 2023, between TransCode Therapeutics, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purcha...",
"TransCode Therapeutics Announces Pricing of $7 Million Public Offering BOSTON, June 6, 2023 -- TransCode Therapeutics, Inc. , an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of its public offering of an aggregate of 2,000,000 shares of its common stock , together with accompanying common stock warrants, at a public offering price of $3.50 per share and accompanying warrants. Each share of common stock is being offered in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $3.25 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $3.25 per share. The Series A-1 warrants will be exercisable immediately and will expire..." |
|
| 06/07/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 06/07/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/05/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 05/19/2023 |
4
| Manting Erik (Director) has filed a Form 4 on Transcode Therapeutics, Inc.|
Txns:
| Granted 45,000 options to buy
@ $0.2834, valued at
$12.8k
|
|
| 05/19/2023 |
4
| Marquet Magda (Director) has filed a Form 4 on Transcode Therapeutics, Inc.|
Txns:
| Granted 45,000 options to buy
@ $0.2834, valued at
$12.8k
|
|
| 05/19/2023 |
4
| Fitzgerald Thomas A (CFO) has filed a Form 4 on Transcode Therapeutics, Inc.|
Txns:
| Granted 300,000 options to buy
@ $0.2834, valued at
$85k
|
|
| 05/19/2023 |
4
| Dudley Robert Michael (CEO) has filed a Form 4 on Transcode Therapeutics, Inc.|
Txns:
| Granted 735,000 options to buy
@ $0.2834, valued at
$208.3k
|
|
| 05/19/2023 |
4
| Calais Philippe (Director) has filed a Form 4 on Transcode Therapeutics, Inc.|
Txns:
| Granted 45,000 options to buy
@ $0.2834, valued at
$12.8k
|
|
| 05/19/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/19/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 05/18/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/10/2023 |
4
| Manting Erik (Director) has filed a Form 4 on Transcode Therapeutics, Inc.|
Txns:
| Granted 9,500 options to buy
@ $0.2985, valued at
$2.8k
|
|
| 05/10/2023 |
4
| Marquet Magda (Director) has filed a Form 4 on Transcode Therapeutics, Inc.|
Txns:
| Granted 9,500 options to buy
@ $0.2985, valued at
$2.8k
|
|
| 05/10/2023 |
4
| Calais Philippe (Director) has filed a Form 4 on Transcode Therapeutics, Inc.|
Txns:
| Granted 9,500 options to buy
@ $0.2985, valued at
$2.8k
|
|
| 05/10/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 04/14/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/31/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/31/2023 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 Interactive Data |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/31/2023 |
8-K
| Quarterly results |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
|
|
|